Patents Assigned to Puget Sound Blood Center
-
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
Patent number: 11286528Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.Type: GrantFiled: January 11, 2019Date of Patent: March 29, 2022Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTERInventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce -
Patent number: 10794921Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.Type: GrantFiled: July 27, 2018Date of Patent: October 6, 2020Assignees: University of Washington, Puget Sound Blood CenterInventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
-
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
Patent number: 10221455Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.Type: GrantFiled: January 12, 2013Date of Patent: March 5, 2019Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTERInventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce -
Publication number: 20170227555Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.Type: ApplicationFiled: February 17, 2017Publication date: August 10, 2017Applicants: University of Washington through its Center for Commercialization, Puget Sound Blood CenterInventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
-
Patent number: 9599613Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.Type: GrantFiled: July 20, 2012Date of Patent: March 21, 2017Assignees: University of Washington through its Center for Commercialization, Puget Sound Blood CenterInventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
-
Publication number: 20140315760Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.Type: ApplicationFiled: July 20, 2012Publication date: October 23, 2014Applicants: PUGET SOUND BLOOD CENTER, University of Washington through its Center for CommercializationInventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
-
Publication number: 20140296105Abstract: Disclosed herein are methods, systems, mediums, and kits for use in phenotyping antibody responses via devices such as surface plasmon resonance devices. Such phentypes can include total target-specific antibody titers, quantitative isotype distribution of the target-specific antibodies, and/or epitope specificity of the target-specific antibodies. Other methods, systems, mediums, and kits are also disclosed.Type: ApplicationFiled: October 31, 2012Publication date: October 2, 2014Applicant: Puget Sound Blood CenterInventors: Kathleen Pratt, Kenneth B. Lewis
-
Publication number: 20140178904Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.Type: ApplicationFiled: August 28, 2013Publication date: June 26, 2014Applicant: Puget Sound Blood CenterInventor: James Charles Zimring
-
Patent number: 8691211Abstract: This invention relates to methods and compositions for suppressing an immune response to Factor VIII in subjects suffering from hemophilia A and having preformed inhibitor antibodies against Factor VIII, and compositions and methods that advantageously render subjects amenable to standard treatments for hemophilia A, including Factor VIII replacement therapy.Type: GrantFiled: March 10, 2010Date of Patent: April 8, 2014Assignee: Puget Sound Blood CenterInventor: Neil Cary Josephson
-
Patent number: 8637268Abstract: Novel methods are described for measuring the rate of ADAMTS13-mediated cleavage of von Willebrand Factor (VWF) multimers. Through the use of the reagent, ristocetin, the method can advantageously be performed in the absence of an applied shear stress or added denaturing agent. Also described are methods for diagnosing ADAMTS13-associated disorders and methods for providing improved treatment of those disorders by evaluating the efficacy of the treatment using the methods as described.Type: GrantFiled: November 4, 2011Date of Patent: January 28, 2014Assignee: Puget Sound Blood CenterInventors: Junmei Chen, Dominic W. Chung, Jose Aron Lopez
-
Patent number: 4998931Abstract: The immunogenicity of transfused or transplanted, allogeneic tissue is reduced by either directly exposing the tissue to ultraviolet (UV) irradiation prior to administering the tissue to the recipient or by inducing a state of tolerance in the recipient to non-UV or UV-irradiated allogeneic tissue by prior exposure to UV-irradiated allogeneic tissue.Type: GrantFiled: December 21, 1988Date of Patent: March 12, 1991Assignees: Puget Sound Blood Center, Fred Hutchinson Cancer Research CenterInventors: Sherrill J. Slichter, H. Joachim Deeg